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Abstract Aim The aim is to study access to intrathecal baclofen (ITB) for children with cerebral
palsy (CP) in Europe, as an indicator of access to advanced care.
Methods Surveys were sent to CP registers, clinical networks, and pump manufac-
turers. Enquiries were made about ITB treatment in children born in 1990 to 2005 by
sex, CP type, level of gross motor function classification system (GMFCS) and age at the
start of treatment. Access to ITB was related to the country’s gross domestic product
(GDP) and % GDP spent on health.
Results In 2011 population-based data from Sweden, Norway, England, Portugal,
Slovenia, and Denmark showed that 114 (3.4%) of 3,398 children with CP were treated
with ITB, varying from 0.4 to 4.7% between centers. The majority of the children were
at GMFCS levels IV-V and had bilateral spastic CP. In Sweden, dyskinetic CP was themost
commonly treated subtype. Boys were more often treated with ITB than girls
(p¼0.014). ITB was reported to be available for children with CP in 25 of 43 countries.
Access to ITB was associated with a higher GDP and %GDP spent on health (p<0.01).
Updated information from 2019 showed remaining differences between countries in
ITB treatment and sex difference in treated children was maintained.
Conclusion There is a significant difference in access to ITB for children with CP across
Europe. More boys than girls are treated. Access to ITB for children with CP is associated
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In cerebral palsy (CP), secondary complications due to spas-
ticity and dystonia are common.1 Pain has been shown to
impact the quality of life of children with CP in a large
multicenter study, the SPARCLEproject (Studyof Participation
of Childrenwith Cerebral Palsy Living in Europe).2 The follow-
up routines and access to intervention regarding spasticity in
CP are thought tovary greatlyover Europe. One example is the
access to intrathecal baclofen treatment (ITB) for severe
spasticity and dystonia.3–5 The continuous administration of
baclofen directly into the intrathecal space requires the
implantation of a pump. This treatment reduces the increased
muscle tone from spasticity and/or dystonia and can improve
sleep, pain management, and quality of life in children with
spastic and dyskinetic CP, and has been shown to be cost-
effective.6,7 Long-term effects in reduction of muscle tone
have been shown.8,9 A recent randomized trial reports prom-
ising results in achieving treatment goals compared with
placebo.10 This advanced treatment is concentrated in a
limited number of centers in each country, usually in connec-
tionwith neurosurgery clinics, and therefore easily surveyed.
As part of a 3-year program, the SCPE-NET (http://www.
scpenetwork.eu) utilized the existing collaboration of 21
population-based registers in 14 European countries—Sur-
veillance of Cerebral Palsy in Europe (SCPE)11 to promote best
practice and to document variations in access to health care
and in health outcomes. As an example of management of
children with CP, ITB was chosen as indicator for access to
advance care. It was hypothesized that the access to this
treatment for children and young people with CP is unevenly
distributed across Europe.
The aimof this studywas to survey the current availability
and access to ITB treatment for children with CP in different
countries in Europe. Moreover, we wanted to describe the
occurrence of ITB treatment in childrenwith CP bygender, CP
type, gross motor function, and age at the start of treatment.
We hypothesized that children with CP living in countries
with a high gross domestic product (GDP)weremore likely to
have access to this treatment than children living in coun-
tries with lower GDP.
Methods
The occurrence of ITB treatment was determined with a regis-
ter-based study. In 2011, a first survey (►Supplementary
Material S1, online only) was sent to SCPE population-based
registry partners and clinical networks, exploring the possibili-
ties of data collection regarding children with CP and ITB.
Registers were asked to provide data on children with spastic
anddyskinetic CPaccording to theCP classificationbySCPE,11at
allGrossMotorFunctionClassificationSystem(GMFCS) levels,12
and born in between 1990 and 2005. Information on centers
providing ITB in the area was elicited. In a second survey
(►Supplementary Material S2, online only), SCPE partners
and clinical networkswilling to contributeprovided aggregated
data on presence of ITB treatment by sex, CP type, GMFCS level,
and age at implant of a baclofen pump.
The availability and access to ITB on national/regional/
local level were explored with a third questionnaire
(►Supplementary Material S3, online only) sent to all CP
registers, SCPE partners, known centers, and clinical net-
works in countries across Europe. Additional information on
the availability in European countries was accessed through
Medtronic, Tricumed, and Codman, manufacturers of medi-
cal pumps. Updated information was requested in 2019.
Availability of ITB treatment was related to economic
indicators by country GDP, percentage of GDP spent on health
for each of the participating countries (% GDP), and the Gini
coefficient, a measure of inequality of income, varying from 0
(complete equality) to 1.0 (complete inequality). Economic
indicators were retrieved from the CIA Factbook.13
Statistics
Group comparisons were made using Chi-square test. The
gender distribution in the dataset was compared with the
gender distribution in the large SCPE common database. Spear-
man’s correlation was used to study correlations between the
presence of ITB treatment and the GDP, % GDP used for health
services and the Gini coefficient.
Results
Aggregated data from population-based registers were pro-
vided by Sweden, Norway, northern England, Portugal (Lisbon
area), Slovenia, and Denmark. In total, 114 of 3,398 (3.4%)
childrenwith CP from the reported areas and birth years were
treated with ITB, ranging from 0.4% in the Lisbon area,
Portugal, to 4.7% in southwestern Sweden. Norway reported
the youngest implant age, with 11 of 24 children receiving ITB
before 5years of age (►Table 1).
Differences in treatment practices across Europe
were found, whereby children with bilateral spastic CP
were the most commonly treated group, except in Sweden,
where children and young people with dyskinetic CP
comprised the largest group. In all, 95% of the treated
children and young people were nonwalkers (GMFCS IV-V).
In addition to the information provided by these popula-
tion-based registers one center in Belgium and four in the
Netherlands provided additional information approximately
80 children in total. These centers reported ITB in occasional
walkers, while the majority of children with ITB were non-
walkers, and age at implant inmost cases was>7 years (range
5–19).
Among all 114 children treated with ITB, 80 (70%) were
boys. This proportion is higher than the proportion of boys
(59%) among 6,849 children and young people born between
1990 and 2004 and registered in the SCPE common database
(χ2¼6.03; p¼0.0141). This sex difference persistedwhen the
comparisonwas restricted to children unable towalk (GMFCS
levels IV-V) (χ2¼4.76; p¼0.029). At country/center level,
27 of 32 responders from CP registers and their clinical net-
works in 22 countries across Europe reported on availability of
ITB for childrenwith CP (►Table 2). Informationgathered from
the manufacturers of medical pumps active in Europe was
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added to this, indicating access to ITB for childrenwithCP in25
of43countries.Access to ITB forchildrenwascorrelated toGDP
per capita (Spearman’s rho¼0.684; p<0.01) and to %GDP
spent on health (Spearman’s rho¼0.589; p<0.01). Therewas
no correlation between access to ITB and the Gini coefficient
(Spearman’s rho 0.217, p¼0.162).
Updated information received in 2019 from Portugal,
Denmark, Northern England, Norway, Slovenia, and Sweden
showed that the occurrence of ITB in Norway, Denmark, and
Sweden was still higher than in Slovenia and Northern
England. An increased occurrence of ITB in Portugal in older
children and young adults was seen (►Table 3). In the
participating area of Northern England there was no ITB
treatment to report. In total, there was still a male predomi-
nance in ITB treatment. However, the sex distribution was
more even in Denmark and Portugal. Incomplete data on age
at implant suggested remaining differences, with more than
half of the baclofen pumps implanted before 5 years of age in
Norway, while all but onewas implanted at 10 years of age or
later, in Portugal (►Table 3).
In 2019, ITB was available in 31 of 43 countries, according
to manufacturers.
Discussion
Basedoncurrent literature, ITB treatment in childrenwithCP is
not yet a standard practice and not yet considered sufficiently
evidence-based to be recommended.14 However, there is con-
sensus on the appropriate use of ITB in childrenwith spasticity
and dystonia.15,16 Evidence on the benefits of ITB is emerging
regarding dyskinetic CP,17 which has been less studied than
spastic CP,16 and a randomized-controlled trial has recently
































M 43 (6.3) 637 17 (4.6) 355 1 (0.7) 143 1 (2.9) 34 3a 15 (2.9) 521
F 13 (2.5) 505 7 (2.7) 256 0 (0) 86 0 (0) 16 1a 13 (3.4) 368
Total 56 (4.7) 1,142 24 (3.8) 611 1 (0.4) 229 1 (2) 50 4 (1.1) 363a 28 (3) 889
GMFCS
I-II 1 (0.001) 702 0 (0) 409 0 (0) 80 0 (0) 27 0 2 (0.4) 507
III 1 (1) 100 1 (0.2) 53 0 (0) 34 0 (0) 5 1 0 (0) 34
IV 10 (5.2) 182 6 (10.5) 51 0 (0) 38 0 (0) 5 0 3 (2) 146
V 44 (22.9) 148 17 (17.2) 82 1 (1.4) 68 1 (100) 1 3 23 (10.5) 197
Unknown 0 10 0 (0) 16 0 9 0 (0) 12 0 0 (0) 5
Total 56 (4.7) 1,142 24 (3.8) 611 1 (0.4) 229 1 (2) 50 4 (1.1) 363a 28 (3) 889
CP type
USCP 0 (0) 406 0 (0) 278 0 (0) 42 0 (0) 16 0 0 (0) 367
BSCP 20 (3.8) 504 20 (7.6) 243 1 (0.7) 154 1 (3) 32 2 19 (4.2) 435
Dysk CP 34 (17.9) 156 4 (7.8) 47 0 (0) 33 0 (0) 2 2 9 (10.7) 75
Mixed 2 (5.7) 33 0 (0) 8 0 (0) 0 0 (0) 0 0 0 (0) 0
Unknown 0 (0) 43 0 (0) 35 0 (0) 0 0 (0) 0 0 0 (0) 12
Total 56 (4.7) 1142 24 (3.8) 611 1 (0.4) 229 1 (2) 50 4 (1.1) 363a 28 (3) 889
Age at
implant
<5 y 4 (7.1) 11 (45.8) 0 (0) 0 (0) 0 (0)
5–9 y 24 (42.8) 8 (33.3) 0 (0) 0 (0) 1 (25)
10 yþ 28 (50) 0 (0) 0 (0) 1 (100) 3 (75)
Unknown 0 (0) 5 (20.8) 1 (100) 0 (0) 0 (0) 28 (100)
Total 56 24 1 1 4 28
Abbreviations: BSCP, bilateral spastic cerebral palsy; CIA, Central Intelligence Agency; CP, cerebral palsy; GMFCS, Gross Motor Function Classification
System; ITB, intrathecal baclofen; USCP, unilateral spastic cerebral palsy.
aNo information of sex distribution, GMFCS distribution, and CP subtypes was received from Slovenia regarding children without ITB. No information
on age of implant was received from Denmark.
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Table 2 Availability of intrathecal baclofen treatment (ITB) for children in European countries, based upon information from three
manufacturers of medical pumps, used for ITB, and information from 32 responders from 22 countries across Europe, reporting
about availability of ITB for children with CP. Gross domestic product (GDP) and percentage of GDP spent on health in the countries
where ITB is available for children with cerebral palsy
European countries where intrathecal baclofen was
available for children with cerebral palsy in 2011
Gross domestic product (GDP) 2011
(International dollar)




Austria 41.7 9.9 0.26
Belgium 37.6 9.5 0.28
Denmark 40.2 9.5 0.24
Finland 38.3 7.6 0.27
France 35.0 11.1 0.33
Georgia 5.4 8.4 0.41
Germany 37.9 10.4 0.27
Greece 27.6 9.9 0.33
Hungary 19.6 7.6 0.25
Iceland 38.0 9.3 0.28
Ireland 39.5 7.5 0.34
Italy 30.1 9.0 0.32
Luxembourg 84.7 7.2 0.26
Netherlands 42.3 9.3 0.31
Norway 53.0 8.7 0.25
Poland 20.1 6.2 0.34
Portugal 23.2 10 0.39
Romania 12.3 5.7 0.33
Slovakia 23.4 7.0 0.26
Slovenia 29.1 8.4 0.28
Spain 30.6 8.1 0.32
Sweden 40.6 8.9 0.23
Switzerland 43.4 11.3 0.34
Turkey 14.6 5.6 0.40
United Kingdom 35.9 8.4 0.34
No ITB available for children in 2011
Belarus 14.9 6.4 0.27
Bosnia Herzegovina 8.2 8.3 0.36
Bulgaria 13.5 6.9 0.45
Croatiaa 18.3 7.5 0.27
Czech Republica 25.9 6.8 0.31
Estoniaa 20.2 5 0.31
Kazakhstan 13 3.7 0.27
Latvia 15.4 6 0.35
Lithuaniaa 18.7 6.2 0.36
Macedonia 10.4 8.2 0.44
Malta 25.7 8.3 0.26
Moldova 3.4 7.8 0.38
Montenegro 11.2 6.8 0.24
Russiaa 16.7 5.3 0.42
Serbiaa 10.7 7.6 0.28
Ukraine 7.2 7 0.28
aIndicates additional countries with confirmed ITB for children in the 2019 update.
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been published, showing that ITB is superior to placebo in
achieving treatment goals in severe dyskinetic CP.10 The long-
term safety and efficacy have been described, and cost-effec-
tiveness of this treatment has been shown.8,9 ITB is frequently
used in some countries, mostly in nonwalkers, to increase
comfort, by reducing spasticity, dystonia, and pain. Some
centers also use ITB for children and young people who
are able to walk, with or without devices, to gain or improve
function, mostly pertaining to mobility and walking.
The present study reveals that children with CP in many
European countries have access to treatmentwith ITB. The use
of ITB was associated with % of GDP spent on health in the
country, which is not surprising. To utilize this possibility,
physicians need to include it in treatment programs for CP. An
obstacle may be that it is considered an expensive treatment,
thus the message of cost-effectiveness must be emphasized.
However, our results at patient level suggest that having
access to ITBmay not mean that the access to ITB is easy. This
is highlighted by the variation of ITB treatment ranging from
0.4 to 4.7% in 2011. Updated information from 2019 suggests
that there is still some variation between countries. Different
treatment traditions, or awaiting further evidence of the
treatment effects may also be possible reasons for not using
ITB, despite increasing availability.
Boys constituted 70% of the total group of children treated
with ITB in this study. The difference in treatment with ITB
between boys and girls does not mirror the actual sex differ-
ence in CP, although there is a male predominance in CP.18
Some authors have described sex differences in children with
CP affecting the surgeon’s choice of orthopedic treatment and
in outcome after interventions.19,20 Other studies report that
boys with CP more often are treated with botulinum toxin21
and more often have physiotherapy.22 One potential explana-
tion for this sex differencemay be that although GMFCS levels
are the same, spasticity and dystonia are less pronounced in
girls althoughwe are not aware of any publications supporting
this speculation. Conversely, in a recent study from the
SPARCLE project, girls reported more pain than boys,23 and a
more likely hypothesis is that girls in fact have less access to
treatment than boys, despite comparable needs.24
Although the SCPE network has members in many
European countries, these are mainly registers, which may
not have close clinical networks. This probably limited the
recruitment of participants in this study. Therefore, the study
does not cover all European countries, and the areas within
countries that have reported may not be representative for
the whole country. One example is Northern England, where
only one baclofen pump had been inserted during the study
period. Thismay not be representative of United Kingdom, as
in other areas, ITB is more frequently used. However, we had
no population-based data from these areas. On country/
center level we have tried to access all centers and manu-
facturers. However, there may be centers or manufacturers
that we have not reached, or who have not replied. Addi-
tionally, the age range of children at data collectionwaswide,
between 5 and 18 years. Thus, the proportion of treated
children in the countries reporting from the lowest ages
may be underestimated.
Larger studies on ITB treatment in children with CP may
lead to further development of treatment standards and
recommendations, based on sound evidence,14 and serve
as a basis for informed decisions about ITB, and as an
argument for ITB in countries and regions that do not yet
offer this treatment to children with CP. Such studies may
also reduce perceived delay in treatment, discussed recently
by Berman et al.25
We conclude that there are significant differences in
access to ITB treatment for children with CP across Europe,
which illustrate the inequalities in health care that these
children face. Furthermore, the frequency of ITB treatment
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nation of knowledge.”
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data to this study.
Medtronic, Tricumed, and Codman manufacturers of
medical pumps used for intrathecal baclofen treatment,
provided information regarding availability of treatment
in European countries.
Table 3 Sex differences and age at implant in reported intrathecal baclofen treatment of children with cerebral palsy from
Denmark, Portugal, Norway, and Sweden 2019. No information about sex or age at implant was received from Slovenia
Country
Birth years
Age at implant (years)
M (%) F (%) <5 5–9 10þ Unknown
Denmark (2004–2007) 12 10 22a
Norway (1999–2013) 37 14 29 17 0 5
Portugal (Lisbon area) (1990–2005) 5 6 0 1 10 0
Sweden (west and south) (2000–2015) 24 11 3 16 16 0
Total 78 (66) 41(34) 32 34 26 27
aNo information on age of implant was received from Denmark.
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